Pirlimycin
(Synonyms: 吡利霉素,U-57930E) 目录号 : GC12836
An antibiotic of the lincosamide class
Cas No.:79548-73-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pirlimycin, a lincosamide antibiotic, is effective against gram-positive bacteria, including Staphylococcus, Bacteroides, Streptococcus, and Plasmodium. It functions via inhibiting protein synthesis in bacteria by inducing premature dissociation of the peptidyl-tRNA from the ribosome.
In vitro: Pirlimycin showed activity against Helicobacter pylori with a minimal inhibitory concentration [MIC] 50 of 4 μg/ml and an MIC90 of 64 μg/ml [1].
In vivo: Cows were treated with 50 mg of pirlimycin via two intramammary infusions per quarter at a 24- hour interval (2-day) for 2, 5, or 8 days. Pirlimycin showed antibiotic therapy against environmental Streptococcus spp and Staphylococcus aureus intramammary individual and combined infections [1]. Specifically, pirlimycin cured environmental Streptococcus spp infections in 66.7% (14/21), 85% (17/20), 100% (14/14) in the 2-day group, 5-day group and 8-day group, respectively. S. aureus infections were cured by the treatment of pirlimycin in 13.3% (2/15), 31.3% (5/16), 83.3% (5/6) in the 2-day group, 5-day group and 8-day group, respectively. Furthermore, S. aureus, S. dysgalactiae subsp dysgalactiae, and Enterococcus spp intramammary infections were eliminated by the extended treatment of pirlimycin in 8-day group [2].
References:
[1]. Westblom, T., Midkiff, B., & Czinn, S. In vitro susceptibility ofHelicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A). European Journal of Clinical Microbiology & Infectious Diseases. 1993; 12(7): 560-562.
[2]. B. E. Gillespie, H. Moorehead, P. Lunn, H. H. Dowlen, D. L. Johnson, K. C. Lamar, M. J. Lewis, S. J. Ivey, J. W. Hallberg, S. T. Chester, and S. P. Oliver. Efficacy of extended pirlimycin hydrochloride therapy for treatment of environmental Streptococcus spp and Staphylococcus aureus intramammary infections in lactating dairy cows. Veterinary Therapeutics. 2002; 3(4): 373-80.
| Cas No. | 79548-73-5 | SDF | |
| 别名 | 吡利霉素,U-57930E | ||
| 化学名 | methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-4-ethyl-2-piperidinyl]carbonyl]amino]-1-thio-L-threo-α-D-galacto-octopyranoside | ||
| Canonical SMILES | CC[C@@H]1CCN[C@H](C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O)C1 | ||
| 分子式 | C17H31ClN2O5S | 分子量 | 411.0 |
| 溶解度 | Soluble in ethanol; methanol; DMSO; dimethyl formamide; water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4331 mL | 12.1655 mL | 24.3309 mL |
| 5 mM | 0.4866 mL | 2.4331 mL | 4.8662 mL |
| 10 mM | 0.2433 mL | 1.2165 mL | 2.4331 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet